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Uterinecarcinosarcomas(MMMT—malignantmixedM¨ ulleriantumours)arehighlyaggressive,rare,biphasictumourscomposed
of epithelial and mesenchymal elements believed to arise from a monoclonal origin. While hysterectomy with bilateral salpingo-
oophorectomy remains the mainstay treatment, high rates of recurrence and metastases suggest a need for lymphadenectomy and
postoperativeadjuvanttreatment.Therearenoestablishedconsensusguidelinesfortherapeuticpatientmanagement.Thoughwell
recognized that it improves locoregional control, the role of radiation in improving overall survival outcomes remains undecided.
Although various combinations of chemotherapy have been explored, an optimal therapeutic modality is yet to be determined. As
overallsurvivalrateshavenotimprovedinthirtyyears,itissuggestedthattargetedchemotherapyand/oramultimodalityapproach
may yield better outcomes. This paper provides a summary of the aetiopathogenesis of carcinosarcomas (MMMT) limited to the
uterus with special emphasis on the controversies in the management of these patients.
1. Embryology and HistoricalPerspectives
The name “malignant mixed M¨ ullerian tumor” (MMMT) is
derived from observations of the embryonic female genitalia.
During the sixth week of embryogenesis, the M¨ ullerian
(paramesonephric) ducts created from intermediate meso-
derm of the coelomic epithelium invaginate lateral to the
mesonephric ducts. Epithelial and mesenchymal structures
ariseorareinducedfromthedevelopmentoftheseM¨ ullerian
ducts [1]. In males, anti-M¨ ullerian hormone secreted by the
Sertoli cells of the testis causes rapid regression of these
ducts;however,infemales,thisductleadstotheformationof
the fallopian tubes, uterus, cervix, and cranial portion of
the vagina. Certain M¨ ullerian-type carcinomas have been
identiﬁed, and metaplastic transformation of these carci-
nomas into sarcoma has been suggested on the basis of
clonalityanalysis[2].Thisisfurthersupportedbytheﬁnding
that aside from the uterus, MMMTs have been identiﬁed,
in decreasing order of frequency in the vagina [3], cervix
[4], ovary [5], and most rarely the fallopian tube [6].
Additionally, on rare occasions, the female peritoneum can
develop M¨ ullerian-type neoplasms including MMMT [2].
For over 150 years, malignant neoplasms arising in
the uterus composed of both epithelial and mesenchymal
elements have been a subject of debate. Its origin dates back
to 1852, wherein it was recognized as a mixed mesodermal
tumour that was then called “enchondroma” [1]. Tradition-
ally, MMMTs were thought to be primarily sarcomatous, and
therefore, clinical trials and advances in treatment protocols
followed this guideline. This assumption has since changed,
with the carcinomatous component being favoured as the
primary determinant of tumour aggressiveness resulting in
a change in the management styles.
Our current understanding is that an MMMT is a bipha-
sic tumour of the female genital tract, composed of epithelial
and mesenchymal tissues. Alternative names in the literature
include “malignant mesodermal mixed tumour,” “metaplas-
ticcarcinoma,”and“carcinosarcoma”[7].Thenomenclature
presently in vogue in North America is “carcinosarcoma”
ratherthanMMMT,andtherefore,“uterinecarcinosarcoma”2 Obstetrics and Gynecology International
is used for this tumour in the remainder of the paper. Based
on their sarcomatous component, two categories of uterine
carcinosarcomas have been identiﬁed: homologous and het-
erologous.Thehomologous-typehasasarcomacomposedof
tissues native to the uterus such as endometrium or smooth
muscle whereas in the heterologous-type cartilage, skeletal
muscle, or bone is present which is not native to the uterus.
2.MaterialsandMethods
Using PubMed and Google Scholar, a literature search
was performed using the text phrases “Malignant Mixed
M¨ ullerian Tumor,” “MMMT,” and “uterine carcinosarcoma”
limited to review articles in English published in the last
tenyears(2000–present).Articleswereadditionallyrestricted
to carcinosarcomas of the uterus with exclusion of those
describing this tumour arising elsewhere. The PubMed
“Related Articles” feature identiﬁed additional relevant arti-
cles. The reference lists from these retrieved papers were
analyzed to identify additional relevant publications. This
process was then repeated twice: (a) with the same key
words to identify all papers (case reports, series, and studies)
conducted in the past two years (2009–2011) in order to
report the most up-to-date ﬁndings and (b) with the same
key words in combination with “MRI,” “CT,” and “PET”
without the date constrictions due to a paucity of material
retrieved initially. All relevant publications were collected
and reviewed. In total, 74 documents were analyzed in detail
and the ﬁndings are summarized in this paper.
From the collected bank of references, all studies con-
ducted in the past three years (2008–2011) with n>
500 were selected for in-depth review. Six papers [8–13]
were identiﬁed. Collectively consisting of 13,388 patients,
the demographics and treatment modalities of these major
studies are analyzed in detail and discussed in this paper.
3. Epidemiology
Carcinosarcomas though rare, representing less than 5%
of all uterine tumors [2], account for 16.4% of all deaths
caused by a uterine malignancy [14]. The age-adjusted
rate of uterine carcinosarcoma is reported at 0.6/100,000
[11]. Incidence of women over 35 years of age aﬀected
by carcinosarcoma is 1.8 white and 4.3 black women per
100,000 in the United States [15]. Afro-American women
are at a greater risk of developing carcinosarcomas when
compared with Caucasians, at a 2.2 to 3.0 ratio [11]a n d
thus carcinosarcoma patients are more often nonwhite (23%
versus 15%) [16]. However, detailed comprehensive analysis
of the six indexed large case-based studies [8–13] show
trends that do not support this traditionally held race
distribution pattern (Figure 1). Women are usually over the
age of 50, with most cases occurring between the sixth and
seventh decade [17], with a median age of 62 years [18]a s
demonstrated in Figure 2.
Risk factors for the development of carcinosarcoma are
similar to those of endometrial carcinoma and include
nulliparity, advanced age, obesity, exposure to exogenous
estrogens, and long-term use of tamoxifen [19, 20]. Tamox-
ifen is associated with a 2–7x greater risk of develop-
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Figure 1: This column-graph demonstrates the race distribution
among the six chosen index large case-based series of Bansal et
al. [8], Clayton Smith etal. [9], Garg et al. [10], Garg et al. [11],
Nemani et al. [12] ,a n dW r i g h te ta l .[ 13]. The y-axis indicates the
percentage of patients in the respective study that fall into each
category. Contradictory to the commonly held belief that Afro-
Americans are more likely to develop uterine carcinosarcoma than
Caucasians,allsixstudieshadawhitepopulationmuchgreaterthan
the Afro-Americans.
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Figure 2: This column graph demonstrates the age distribution
among the four of the six index large case-based series of Bansal
et al. [8], Garg et al. [10], Nemani et al. [12], and Wright et
al. [13]. Garg et al. [11] and Clayton Smith etal. [9] are not
included, as this data was not provided. The numbers on top
of each bar indicates the age range it comprises, as each study
categorized patients within diﬀerent age groupings. This graph
demonstrates the predominance uterine carcinosarcomas have for
an older, postmenopausal population.
ing endometrial malignancies. Speciﬁcally, carcinosarcomas
have been reported to occur 7–20 (median of 9 years) years
after the initiation of this regime [21]. On the contrary,
oral contraceptives are reported to provide a protective eﬀect
against these tumours [16].
4.Aetiology
Carcinosarcomas are composed of two histological subtypes
which are classiﬁed based on the appearance of the sar-
comatous component. The sarcoma of heterologous type
has been described as rhabdomyosarcoma, chondrosarcoma,Obstetrics and Gynecology International 3
osteosarcoma, or liposarcoma, whereas the homologous
type tends to be ﬁbrosarcoma, endometrial stromal sar-
coma, or leiomyosarcoma. In both cases, the carcinomatous
component may be composed of endometrioid, serous,
or clear cell type [22]. Aetiological factors implicated in
the development of this cancer include pelvic exposure to
irradiation, obesity, nulliparity, and exposure to the human
papilloma virus or exogenous estrogen [23]. Identiﬁcation
of these two individual components of carcinosarcomas
has sparked theorization to their origin, of which three
predominant theories are proposed [19, 22].
(1) Thecollision theory suggeststhat the twocomponents
hadseparatepointsoforiginpriortotheir“colliding”
together to form a single tumour.
(2) The combination theory postulates that a common
stem cell precursor undergoes bidirectional diﬀer-
entiation that results in the creation of the two
histological types.
(3) In conversion theory, a single epithelial component is
hypothesized to undergo metaplastic diﬀerentiation
from which the mesenchymal component is derived.
It is currently believed that carcinosarcomas have a
monoclonal origin from a common multidirectional pro-
genitor stem cell. Though epithelial markers are expressed
in more than 60% of the sarcomatous component, mes-
enchymal marker expression is rare in the carcinomatous
element [1]. Clinical, pathological, and molecular obser-
vations suggest that these neoplasms are derived from the
M¨ ullerian epithelium’s single stem cells, with metaplasia
or dediﬀerentiation resulting in the sarcomatous elements
[1]. Such a monoclonal origin may be explained by both
the combination and conversion theories [7]. Cell cultures,
ultrastructural studies, and immunohistochemical analyses
all support the conversion theory for the tumorigenesis of
thisneoplasm [22].Traditionally, carcinosarcomaswereclas-
siﬁed as sarcomatous; however, recent evidence suggests that
the epithelium may be the principle “driving” component.
The histogenesis still remains poorly deﬁned [14].
Despite the majority of reports supporting the conver-
sion theory, there remains a percentage of carcinosarcomas
with a biclonal origin [7]. Though 70%–80% of staining
with p53 is identical between the sarcomatous and the
carcinomatous components, 10%–15% of cases have distinc-
tive morphologies, suggesting diﬀerent origins [24]. It is,
therefore, suggested only a small subset of carcinosarcomas
may be “true” collision tumours [25].
Carcinosarcomas may be a radiation-inducible tumour.
Twenty years ago, it was reported that pelvic irradiation may
be implicated in the development of extremely aggressive
uterine cancers, particularly sarcomas. At this point, it was
noted that in one study, ﬁve of the eight patients with uterine
malignancies had a previous pelvic malignancy treated by
radiation [26]. It is now estimated that 5%–30% of patients
with carcinosarcoma have a history of pelvic irradiation.
These neoplasms will often be diagnosed after a latent period
of14yearsafterirradiation[27].ArecentstudybyCallisteret
al. found that 11% patients diagnosed with carcinosarcoma
Table 1: Typical patient proﬁle presenting with uterine carcinosar-
coma.
(i) Elderly female (usually 60–70 years), usually postmenopausal
(ii) Presents with pyometra with vagina bleeding, bloody/watery
discharge, abdominal pain, and/or mass
(iii) Often past history of tamoxifen use
(iv) May be obese, hypertensive, nulliparous, and/or diabetic
(v) No previous history of uterine problems
had a history of prior pelvic radiation therapy, 17 for
malignant, and 15 for benign disease, which negatively
inﬂuenced pelvic control[28].
5.ClinicalFeatures
The clinical presentation of carcinosarcomas may be non-
speciﬁc, with symptoms that are similar to other pelvic
neoplasms [29]. A typical presentation of carcinosarcoma
includes pyometra with vaginal bleeding, bloody or watery
discharge, abdominal pain, or as a polypoid mass in an
older, postmenopausal woman, as listed in Table 1 [7]. At
physicalexam,50%–95%ofpatientshaveenlargementofthe
uterus with 50% of patients having protrusion of a polypoid
lesion through the endocervical canal [23]. The “symptom
triad” indicative of carcinosarcoma rather than endometrial
adenocarcinoma includes pain, severe vaginal bleeding, and
the passage of necrotic tissue per vaginum [27]. Additionally,
patients may be asymptomatic or present with anemia [15].
Patients are often overweight and hypertensive and may be
d i a b e t i co rh a v ep o o rp e r f o r m a n c es t a t u s[ 30]. Aside from
the physical exam, routine pretreatment assessments also
include blood work and chest X-rays, as well as pyelography,
cystoscopy, proctoscopy, and bone scans if required [31].
ElevatedlevelsofserumCA-125havealsobeenreportedwith
this neoplasm [32].
The pathological staging and histological features of the
carcinomatous component of carcinosarcoma are responsi-
ble for the tumour’s biological potential and aggressiveness.
Increased aggressiveness is associated with atypical carci-
nosarcomas with unusual neuroendocrine or melanocytic
diﬀerentiations [33]. Over half (53%) of carcinosarcoma
patients present with advanced-stage disease [16]. Of
patientswithlocalizedcarcinosarcoma,20%willbeupstaged
at laparotomy due to the presence of regional lymph node
metastases [34]. A simple working classiﬁcation for the
staging of carcinosarcoma tumours is as folows: stage I
tumours are conﬁned to the corpus uteri, stage II tumours
involves both the corpus and the cervix, stage III tumours
are limited the lesser pelvis, and stage IV tumours have
extrapelvic extension.
6.Pathology
6.1. Gross Features. Uterine carcinosarcoma’s gross histo-
logical appearance is usually that of a solitary polypoid
mass with regions of haemorrhage and necrosis projecting
into the uterine cavity [35]. Gritty or hardened areas may4 Obstetrics and Gynecology International
suggest osseous or cartilaginous diﬀerentiation [16]. In 50%
of patients, a polypoid mass within the endocervical canal
is present [23]. Within the uterus, carcinosarcomas most
commonly arise on posterior wall of uterine body near the
fundus [29]. The mass is generally large and soft, and grows
toﬁllanddistendtheuterus[23].Duetoincreasedcellularity
and sarcomatous diﬀerentiation, tumours may be bulkier,
ﬂeshier, and larger than endometrial adenocarcinomas [16,
36]. Advanced disease at clinical presentation is found
in approximately 60% of patients, with gross evidence of
tumour extension beyond the uterus [7].
6.2.MicroscopicFeatures. Carcinosarcomasarecharacterized
by their unique biphasic morphology, a tumour composed
of both epithelial and mesenchymal elements. Microscop-
ically, these two elements may be intermittently mixed or
be seen as two distinct components [37]. The epithelial
component is oftena high-grade carcinoma such as papillary
serous (66%) or endometrioid (42%) [7] though it may be
composed of a variety of histological subtypes including
squamous cell carcinoma, basaloid squamous carcinoma,
adenocarcinoma, adenosquamous carcinoma, adenobasal
carcinoma, adenocystic carcinoma, or an undiﬀerentiated
carcinoma [3]. Unlike conventional adenocarcinomas, solid
areas of marked pleomorphism, bizarre cells, embryonal
glandular growth patterns and lace-like arrangement of cells
may be present [16]. The mesenchymal element may be
(a) homologous, containing cells native to the uterus inclu-
ding stromal sarcoma, ﬁbrosarcoma, undiﬀerentiated sar-
coma, or leiomyosarcoma (2%) or (b) heterologous with
mixed components including rhabdomyosarcoma (18%),
chondrosarcoma (10%), osteosarcoma (5%), or liposarcoma
(1%).One-thirdofcarcinosarcomashavetwoormoresarco-
matouselements,withhigh-gradestromalsarcomabeingthe
most common type [7]. Choriocarcinoma and melanocytic
diﬀerentiation are unusual [33, 37].
6.3. Immunohistochemical Features. Carcinosarcomas exp-
ress epithelial (epithelial membrane antigen (EMA), pancy-
tokeratin) and stromal lineage markers in relation to their
histological appearances such as desmin in muscle diﬀer-
entiation or S100 in areas with chondroid or lipomatous
diﬀerentiation. A number of studies have attempted to
evaluate the diﬀerences of protein expression between the
two components as prognostic/predictive markers, however,
often resulting in inconclusive results. This perhaps is
attributedto(a)rarityofthisneoplasm,(b)smallsamplesize
of case series, (c) tumour heterogeneity, and (d) variations in
methodology limiting comparative analysis.
Besidesthestudyoflineageimmunohistochemicalmark-
ers to establish aetiopathogenesis in carcinosarcomas, there
are a number of case studies and reports on cell cycle
proliferative markers and apoptotic regulatory proteins that
explore the possibility of identifying molecular proﬁles
as potential therapeutic targets or markers of prognosis
[24, 38]. Overexpression of tyrosine kinase receptors such
as HER-2, EGFR, and KIT suggest potential targets for
therapeutic use in subgroups of carcinosarcoma [32, 39–42].
7.Radiology
Traditionally, diagnosis of carcinosarcoma is most often
made postoperatively by histological examination and
immunohistochemical studies. Current research is aimed at
determining preoperative imaging criteria to diﬀerentiate
this tumour type from other uterine malignancies, par-
ticularly endometrial carcinomas due to the diﬀerences in
treatment and prognosis. Preoperative diagnosis of uterine
carcinosarcoma will facilitate the planning of appropriate
surgical management with adjuvant therapy.
7.1. Magnetic Resonance Imaging (MRI). Initial characteri-
zations of uterine carcinosarcoma by MRI as outlined by
Worthington (n = 4) in 1986 described carcinosarcoma
as a large mass in the pelvis that entirely obliterated
the architecture of the uterus, with inhomogeneously low
intensityofT1W1andaheterogeneousappearanceonT2W1
[15, 43]. These ﬁndings were further supported in 1980
when imaging studies by Shapeero and Hricak (n = 7)
documented deep tumour invasion of themyometrium [44].
Current literature disagrees with these ﬁndings, concluding
thatmostcarcinosarcomasarevisualizedasexophyticlesions
with no evidence of invasive growth. This discrepancy may
be partially due to diﬀerent clinical stages of the lesions
examined or because of increasing spatial resolution of
MR images over the past twenty years allowing for better
distinction of the border between the tumour and the
myometrium [15].
More recent studies report most of these tumours to be
sharply demarcated [44] with endometrial cavity distension.
In the recent study by Bharwani et al. in 2010, one
of the largest series to study MRI characteristics (n =
51) 76% of tumours were well deﬁned with 61% having
irregular margins. Only 12% were reported as aggressive
with architectural destruction. On T1-weighted images, the
majority of uterine carcinosarcomas were isointense to the
myometrium (76%) and the endometrium (71%) compared
withendometrialcarcinomathatwasisointensetoboththese
elements in 59% of cases. T2-weighted images found hyper-
intensity of uterine carcinosarcomas to the myometrium
(92%) and hypointensity (55%) or isointensity (41%) to
the endometrium, a ﬁnding that is highly comparable to
endometrial carcinoma (97% hyperintense to myometrium,
23% isointense, and 68% hypointense to endometrium).
The craniocaudal dimension of uterine carcinosarcoma was
larger than endometrial carcinoma. This study found 88%
of uterine carcinosarcomas to be indistinguishable from
endometrial carcinoma on MRI. There was no signiﬁcant
diﬀerenceintheextentofmyometrialinvasionbetweenthese
two lesions [45]. These results support the ﬁndings of the
2008 investigation by Tanaka et al. (n = 17) that reported
uterine carcinosarcomas to be large exophytic tumours with
minimal uterine architectural destruction [15].
Though on MRI uterine carcinosarcomas may be
indistinguishable from endometrial carcinomas, their poor
prognosis necessitates radiologists to consider them in the
diﬀerential diagnosis of strongly enhanced uterine lesions
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myometrium suggests the possibility of this tumour-type
[45]. Clinicopathological correlation with MR images is
often necessary to accurately diagnose these rare tumours
preoperatively [36].
7.2. Computed Tomography (CT). Imaging of uterine car-
cinosarcoma by CT scans is not as well-described as MRI
studies. The appearance of uterine carcinosarcoma is not
pathognomonic and can be easily mistaken for lesions
such as leiomyosarcomas or endometrial carcinomas [46].
Dilatationoftheuterusisacommonﬁndingreportedin90%
and 73% of patients in two studies [46, 47]. In one study,
myometrialinvasionwasevidentin80%ofpatients,detected
by contrast-enhanced computed tomography (CECT) by
the diﬀerences in attenuation between the tumour and the
myometrium. It was further recognized that CECT has
potential for tumour staging, with a reported accuracy of
89%. This modality shows the tumour to be a heterogenous,
hypodense, ill-deﬁned mass [47].
7.3. Transvaginal and Transabdominal Sonography. Sonog-
raphy is a noneﬀective investigation for uterine carcinosar-
coma. Doppler imaging may be unable to (a) accurately
predict tumour stage, (b) evaluate the retroperitoneum, and
(c) evaluate the deep pelvic lymph node chains [47]. Though
most Doppler ultrasonography is able to detect areas of
neovascularization associated with malignant tumours, it
was not able to detect the hypervascularity of a uterine
carcinosarcoma in a reported case [48]. These tumours are
inhomogeneously echoic, with small cystic spaces that are
anechoic [47].
7.4. 18F-Fluorodeoxyglucose Positron Emission Tomography
(18F-PDG PET) Scans. Though scarcely reported in the
literature, 18F-PDG PET scans show potential in the detec-
tion of metastases from uterine carcinosarcomas. Malignant
tissue has a greater rate of glucose metabolism than benign;
therefore, suspected malignancies and their metastases can
be visualized [48]. One study researching four uterine
sarcomas and one uterine carcinosarcoma found 18F-FDG
PET was able to accurately predict all ﬁve primary malig-
nant tumours, whereas MRI predicted four of them, and
ultrasound only two [49]. 18F-PDG PET scan use by Ho et
al. allowed for 36.8% of the patients in their study to be
re-evaluated, two-thirds for monitoring response and one-
ninth to be restaged. Though this modality appears to oﬀer
the possibility of earlier detection of metastases, there was
no reported improvement in patient outcome data in this
study [31]. Another study by Murakami et al. suggests that
in patients with recurrent uterine carcinosarcomas, FDG-
PETmayincreaseprolongedsurvival,especiallyinthosewith
small tumours treated with combination therapy [50]. 18F-
PDG PET scans seem to have limited value in posttherapy
surveillance or restaging after failure with recurrence [31].
8. Treatment
To date, no national consensus guidelines have been estab-
lished for the management of uterine carcinosarcomas [36].
The optimal treatment remains uncertain, partially because
the histogenesis remains controversial [5]. Therapeutic
approaches may diﬀer depending on the precursor lesion
[14]. Chemotherapy eﬀectiveness in sarcomas diﬀers greatly
from that in endometrial carcinomas, with increased toxicity
[51]. A full understanding of the pathobiogenesis of this
tumourisnecessarytopredictthe“goldstandard”treatment.
As it is currently believed that uterine carcinosarcoma is
akintoametaplasticendometrialcarcinoma,mosttreatment
plans have been modeled based on treatment protocols for
high-risk endometrial carcinoma [19].
Theprimarytreatmentoption remainssurgery;however,
high rates of relapse and metastases postoperatively necessi-
tate eﬀective adjuvant therapies [28]. As research continues
to elucidate the natural history of uterine carcinosarcomas,
with recognition of the high rates of recurrence and distant
metastases, it is proposed by some authors that systemic
chemotherapy should replace radiotherapy as the primary
modality of adjuvant treatment [52]. Regardless, in higher-
staged tumours, neither radiotherapy nor chemotherapy
provides any signiﬁcant overall survival beneﬁt [53]a n d
there remains to date no consensus to guide therapeutic
strategies for the various stages of disease [14].
Despite advances in adjuvant therapy, the past four
decades have not seen any measurable improvement in
survival. It is, therefore, suggested that the primary curative
treatment is surgical resection [28]. A multimodality treat-
ment plan has been suggested, with results indicating that
surgery followed by a combination of both chemotherapy
and radiation therapy yields a signiﬁcantly longer median
disease-speciﬁc survival (DSS) of 31 months versus surgery
alone (DSS = 3 months), radiation therapy alone (DSS =
15 months), or chemotherapy alone (DSS = 14 months)
[14]. These ﬁndings are further supported by a study by
Menczer et al. demonstrating that uterine carcinosarcoma
patients undergoing sequential treatment of chemotherapy
and irradiation not only have less toxic events, but also have
a 50% and 80% decreased mortality compared to patients
taking irradiation and chemotherapy alone [54].
8.1. Surgery. Although total abdominal hysterectomy (TAH)
with bilateral salpingo-oophorectomy (BSO) is the preferred
standard surgical option, the additive beneﬁt for the role of
lymphadenectomy remains undetermined [55]. The current
surgical practice recommended for uterine carcinosarcoma
is surgical staging with TAH with BSO, pelvic lymphadenec-
tomy, and para-aortic lymph-node sampling with peritoneal
washings. The role of pelvic and para-aortic lymph-node
sampling, the method, technique of dissection, and the
optimal number of lymph nodes to be sampled remains
undetermined [12]. For patients with advanced disease,
cytoreduction surgery is recommended based on their pre-
vious experiences with ovarian and other uterine neoplasms
[7, 56]. In 2010, Garg et al. studied this relationship and
found that the risk of death decreased 33% in patients that
underwent a lymphadenectomy when compared to those
that did not [11]. These results are similar to Nemani’s
results, that reported a median survival of 54 months in
patients who underwent a lymphadenectomy (5-year overall6 Obstetrics and Gynecology International
survival of 49%) compared to 25 months in those that did
not (5-year overall survival of 34%) [12]. Other studies
have found the addition of lymphadenectomy to be an
independent positive prognostic factor [8, 10].
Three primary arguments in support of conducting a
lymphadenectomy in all patients with uterine carcinosar-
coma have been put forward, including (a) accurate staging
will allow the determination of the patient’s true “metastatic
risk”, (b) possible reduction in locoregional recurrences
within the lymph nodes, and (c) improving selection of
patients for adjuvant therapy. Lymphadenectomy oﬀers
a survival advantage only for node-negative patients, as
removal of positive nodes upstages the disease and worsens
the prognosis. By contrast, “negative nodes” may contain
micrometastatic foci that, when removed, does decrease
the risk of the development of macrometastases [55]. In
Nemani’s study, 14% patients had positive nodes at lym-
phadenectomy. Node-negative patients may then be referred
for adjuvant therapy. Prognosis is signiﬁcantly improved in
patients who receive both lymphadenectomy and adjuvant
radiotherapy when compared with those who were treated
by hysterectomy and bilateral salpingo-oophorectomy alone
[12]. In 2010, Vorgias and Fotiou reviewed the uterine
carcinosarcoma literature and found that between 35% and
57% of uterine carcinosarcoma surgeries carry out lymph
node dissection though the extent ranges from biopsy to
complete pelvic lymphadenectomy [55]. The number of
nodes removed has been reported to have no signiﬁcant
impact on overall survival by some authors [12]; however,
othershavefoundthatinearly-stageuterinecarcinosarcoma,
the number of nodes removed is a risk factor correlated
with both recurrence and survival [34]. Congruent with
these ﬁndings, a recent publication by Garg et al. in 2011
concludes that the optimal patient management for uterine
carcinosarcomas includes abdominal hysterectomy, bilateral
salpingo-oophorectomy, lymph-node dissection, resection
of gross abdominal disease, and sampling of peritoneal
washings [10]. Despite this conclusion, composite data
analysis of the six large index case series as seen in Figure 3
illustrate that a substantial percentage of patients are still not
receivinganylymph-nodedissectioneithersynchronouslyor
metachronously in conjunction with their TAH + BSO.
8.2. Radiotherapy. It is well established that radiotherapy
contributes to decreased pelvic recurrences; however, the
impact this adjuvant postoperative therapy has on patient
survivalremainsasubjectofcontroversy.Datadescribingthe
relationship between survival and uterine carcinosarcomas is
limited [55]. Recognition of the high levels of recurrence and
metastatic spread associated with uterine carcinosarcomas
has called for a re-evaluation of the role of adjuvant radio-
therapy in patient management. Due to small sample sizes,
limitedsurgicalstagingdataandlackofstratiﬁcationofprog-
nostic factors, it is diﬃcult to make conclusions based on the
current literature [57]. As seen in Figure 4, though patients
are more likely not to receive radiotherapy, the diﬀerences
amongst the large case-based series are not signiﬁcant.
Some studies have found pelvic irradiation yielded only
slight improvement in pelvic recurrence rate presumably
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Figure 3: This column graph presents the percentage of patients
who underwent lymphadenectomy among ﬁve of the six chosen
index large case-based series of Bansal et al.[8], Garg et al. [10],
Garg et al. [11], Nemani et al. [12], and Wright et al. [13]. Clayton
Smith et al. [9] is not included as this data was not provided. This
graph demonstrates that despite convincing evidence indicating the
importance of lymphadenectomy as part of surgical treatment of
uterinecarcinosarcomas,asubstantialproportionofpatientsdonot
undergo lymph-node dissection.
because of the increased tendency for intraperitoneal reseed-
ing. Though radiation therapy may improve locoregional
control, demonstration of a survival advantage remains
uncertain [10]. Callister et al. (n = 300) associated adjuvant
radiation therapy with lowered pelvic recurrence rate and a
decreasedtimeintervaltodistantmetastaticspread;however,
no statistically signiﬁcant overall survival beneﬁt was found
[28]. Sartori (n = 118) additionally found no improvement
in 5-year disease-free survival (DFS) in patients receiving
postoperative radiation [58]. It is suggested that the inability
of studies to show statistically signiﬁcant overall survival
(OS) rates in patients receiving adjuvant radiotherapy may
be due to the diﬀerence between clinical and surgical staging,
as 9% of patients with “early clinical stage” will be upstaged
to stage III and 10% to stage IB because of metastases,
thus diminishing the possible long-term survival eﬀects of
radiotherapy. It is also suggested that by extending the ﬁeld
of radiation to include the abdomen and the regional lymph
nodes, patients who are upstaged may receive some beneﬁt
from this technique [57].
In contrast, other studies have demonstrated a prolonged
DFSinpatientswithearly-stagediseasetreatedwithadjuvant
radiotherapy [1] .I nas t u d yb yC l a y t o nS m i t he ta l .( n =
300), radiation therapy increased 5-year survival rates from
33.1% (patients not receiving adjuvant radiation therapy)
to 42.4% (patients receiving adjuvant therapy. Multivariant
analysis further reported adjuvant radiation therapy con-
ferred beneﬁts for both overall and uterine-speciﬁc survival
in women stages I–IV, with the greatest impact on Stage IV
disease [9]. The beneﬁts of radiation therapy were further
elucidated by Nemani et al. (n = 1697) who demonstratedObstetrics and Gynecology International 7
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Figure 4: This column-graph shows the percentage of patients that
underwent radiation therapy in each of the six chosen index large
case-based series of Bansal et al. [8], Clayton Smith etal. [9], Garg
et al. [10], Garg et al. [11], Nemani et al. [12] ,a n dW r i g h te ta l .
[13]. Though in ﬁve of the six studies more patients did not have
radiation therapy as part of their treatment regime, the diﬀerence
is not signiﬁcant. This is probably best explained by the remaining
unansweredcontroversythatquestionstheimprovementinsurvival
rates associated with this modality of adjuvant therapy.
a median survival increase from 23 months to 29 months
in patients who had not undergone lymph-node dissection
with a 5-year OS increase from 33.4% to 35.8% [12]. These
ﬁndings were supported the same year by Wright et al.
(n = 1819) who also found that in patients with no history
of lymphadenectomy, radiation therapy reduced mortality
rates by 25% [13]. In patients with early-stage uterine
carcinosarcomas, rates of pelvic recurrence when treated
with modern radiotherapy techniques do not exceed 10%
[57]. Controversies still remain regarding the techniques of
radiation:localizedpelvicradiationbyvaginalbrachytherapy
versus whole abdominal radiation by external beam [59].
8.3. Chemotherapy. Despite surgical extirpation of the pri-
mary tumour, sites of failure occur in both pelvic and
extrapelvic regions. Pelvic radiation does not eliminate
pelvic relapse. Extrapelvic recurrence/relapse is common
with hematogenous, transcoelomic, and lymphatic spread
of the tumour; therefore, chemotherapy has a deﬁnitive
role to minimize both local and distal failure [60, 61].
Identiﬁcation of eﬀective chemotherapeutic agents to treat
patientswithuterinecarcinosarcomasisessentialduetosuch
high incidence of disseminated disease at presentation. In
light of the continuing sarcomatous versus carcinomatous
debate, traditional adjuvant chemotherapeutic regimes have
been created based on the model employed for high-
grade sarcomas such as leiomyosarcoma and undiﬀerenti-
ated uterine sarcoma [25]. Chemotherapy response rate in
patients with a predominant carcinomatous element yielded
a better overall response rate (87.5%) than those with a
dominant sarcoma [56]. There is no universal agreement
on a postoperative chemotherapeutic regime for uterine
carcinosarcomas [7]. Most studies focus on the development
of postoperative adjuvant treatment for Stage I/II lesions and
palliativetreatmentforadvanced[18].Activesinglecytotoxic
antineoplastic agents include ifosfamide (RR = 29%–36%),
cisplatin (RR = 28%–42%), doxorubicin (RR = 10%–25%),
and paclitaxel (18%) [62]. Response rates (RR) to cisplatin
are 19% as a ﬁrst-line and 18% as a second-line agent
againstuterinecarcinosarcomas.RRtopaclitaxelis18%with
4-month duration [63]. Certain single chemotherapeutic
agents of note proposed since 2005 are herein summarized.
(i) Sorafenib [64]. Sorafenib acts by inhibiting wild-type
Raf-1, mutant B-Raf and several receptor tyrosine kinases
such as vascular endothelial growth factor receptors
(VEGFR). Though commonly used to treat renal cell carci-
noma and hepatocellular carcinoma, the Ras/Raf/Mek/MAP
pathway is suggested to play a role in uterine cancers. In this
context, 16 patients with uterine carcinosarcoma were given
amedianof28daysofsorafenibcycles.Adverseevents(grade
3+) included hypertension (13%), hand-foot syndrome
(13%), hypophosphatemia (7%), and hyponatremia (7%).
No objective RR was seen, and the median OS was 5.0
months (range 1.4–14.0 months) with a progression-free
survival (PFS) of 1.8 months (1.4–3.5 months range).
(ii) Topotecan [63]. Topotecan acts as an inhibitor of topoi-
somerase 1 regularly used for ovarian and small cell lung
cancers and active against several sarcomas and gynecologic
cancers. In Miller’s study, 48 patients with advanced, persis-
tentorrecurrentuterinecarcinosarcomaweregivendiﬀerent
dosagesoftopotecan.Toxicitiesincludedneutropenia(73%),
leukopenia (29%), and/or thrombocytopenia (21%) with
three deaths due to neutropenic sepsis. The total RR was
10%, with response duration of 8.3 months.
(iii) Imatinib Mesylate (Gleevac) [65]. Gleevac acts by inhi-
biting the Bcr-Abl tyrosine kinase, PDGFR, and c-Kit. In
Ramondetta’s study [17], 45% of uterine carcinosarcomas
stained positively for Abl and 100% for PDGFR-β. This
chemotherapeutic drug was tested on a series of 23
women in Huh’s study with persistent/recurrent uterine
carcinosarcoma, the majority of which had undergone one
prior chemotherapy regime. PFS greater to six months
only occurred in one patient, with a median PFS of 1.6
months and median survival 4.1 months. Toxicities reported
included fatigue, dehydration, anorexia, and genitouri-
nary/renal/lymphatic/metabolic, and/or ocular toxicities.
The value of combination chemotherapy has become
increasingly notable in the past decade, with an objective
responserate50%higherthanthatreportedwithsinglecyto-
toxic chemotherapeutic agents [51]. Nevertheless, no uni-
versal agreement on the best combination of these drugs has
been established [7]. Similar to carcinomas, uterine carcino-
sarcomasareoftenresponsivetoplatinum-basedchemother-
apies and may be coupled to DNA-alkylating agents with
activity against sarcomas [16]. A variety of agents have been
tested in combination with platinum-based chemother-
apeutic agents, including adriamycin, dacarbazine, and8 Obstetrics and Gynecology International
cyclophosphamide [66]. Though the best-studied combi-
nation has been ifosfamide and cisplatin, disappointing
response rates (18%–44% for single-agent cisplatin and 39%
for single-agent ifosfamide in pretreated patients) limited by
severe side eﬀects necessitates further study [52]. In patients
with high-grade tumours, ifosfamide and cisplatin have
been recognized as highly active agents [18]. Combination
chemotherapeutic agents of note proposed since 2005 are
herein summarized.
(i) Cisplatin and Ifosfamide. RR of the combination of these
chemotherapeutics (54%) has been shown to be signiﬁcantly
greater than that of ifosfamide therapy alone (36%) [62].
A study led by Sutton et al. found a slight advantage in
the median PFS in patients taking this combination when
compared to those on ifosfamide alone. Median PFS was 4.0
months with the single-agent treatment and6.0 months with
the combination, yet no statistically signiﬁcant diﬀerence in
mediansurvivalwasfound[67].Inpatientswithrecurrentor
metastatic disease, this combination has shown to be highly
active agents [18]. This combination of chemotherapeutic
agents compared positively over complete abdominal/pelvic
radiation for all stages of uterine carcinosarcomas although
overall survival did not greatly improve [59]. In Sutton’s
study of 65 early-stage uterine carcinosarcoma patients, he
found24monthPFSandOSat69%and82%,and84-month
at 54% and 52%, respectively [18].
(ii) Cisplatin, Ifosfamide, and Mesna [17]. Sixteen patients,
10 with primary uterine carcinosarcomas, were treated with
this combination, receiving 1–10 cycles of therapy. After
the ﬁrst cycle, two women died from disease progression,
and an additional three were taken oﬀ the treatment due
to toxicity. Of the remaining six women, the mean number
of chemotherapeutic cycles was 3.8. All women experienced
gastrointestinal toxicity and neutropenia was a major side
eﬀect. No complete response occurred and PFS ranged
between 2–4 months.
(iii) Ifosfamide and Paclitaxel [68]. The advantage of com-
bining ifosfamide with paclitaxel as opposed to ifosfamide
as a single agent was explored by Homesley et al. as part
of a Gynecologic Oncology Group (GOG) study. A total
of 179 women were included, 91 of which were treated
with ifosfamide alone and the remaining 88 with ifosfamide
combined with paclitaxel and ﬁlgrastim. Alopecia and severe
sensory neuropathy were most common in the combination
group, whereas nonsevere thrombocytopenia was seen more
in patients receiving the single agent. The odds of a
therapeutic response in patients receiving the combination
was 2.21x greater compared to the solitary agent. Signiﬁcant
diﬀerences in PFS (5.8 months versus 3.6 months) and OS
(13.5 months versus 8.4 months) were additionally noted.
(iv) Paclitaxel and Carboplatin [52, 62]. The Gynecologic
Oncology Group (GOG) led by Powell reports a series of
46 patients with advanced-stage uterine carcinosarcoma,
two-thirds of which were newly diagnosed. The majority
of patients had six or more cycles of paclitaxel-carboplatin
chemotherapy. It was found to be both active and well toler-
ated;therangeofRRsreportedisbetween55%and80%,and
the most common toxicities were hematologic, fatigue, and
peripheral neuropathy. This drug regime was additionally
determined to be nonexpensive, partially because it can be
conducted on an outpatient basis rather than the three-
day inpatient admission required for ifosfamide therapy. It
is suggested that additional biological anticancer therapies
may be added onto this regime. An additional study led by
Lacour et al. reported 23 patients with advanced/recurrent
uterine carcinosarcoma, the majority (69.2%) of which had
previously received radiation therapy, and reported a time to
progression (TTP) of 9.5 months and an OS of 21.1 months.
Similar to the GOG studies, common toxicities included
fatigue, neutropenia, and alopecia. There was no signiﬁcant
diﬀerence between the survival of patients with and without
measurable disease.
(v)GemcitabineandDocetaxel[69].Thiscombinationofche-
motherapeutic agents have been used to achieve RRs of 17%-
18% in advanced soft-tissue sarcomas; therefore, 28 patients
all who had undergone one prior chemotherapeutic regime
were given this combination on a weekly schedule to treat
recurrent disease. The RR was disappointing at 8.3%, with
no complete response, and a partial response was obtained
in only two patients. The median PFS was 1.8 months,
and median survival was 4.9 months. Toxic eﬀects included
myelosuppression, thrombocytopenia, and anaemia.
Additional chemotherapeutic agents that have been eva-
luated include piperazinedione, etoposide, mitoxantrone,
diaziquone, amonaﬁde, aminothiadiazole, and topotecan;
however, they did not demonstrate signiﬁcant results [63].
Theeﬀectivenessofchemotherapeuticagentsdecreasesinthe
treatmentofdistantmetastases[70].Responseratesofrecur-
rent disease are reported at 18%–36% (ifosfamide), 19%
(doxorubicin), 18%-19% (cisplatin) and 9%-10% (topote-
can) with gemcitabine and docetaxel having a low response
rate [7]. Regardless of whether the chemotherapeutic regime
employed is a single or combination agent, treatment of
uterine carcinosarcoma will likely have more toxic eﬀects
than treatment of endometrial adenocarcinomas [51].
It has been suggested that the future of uterine carci-
nosarcoma therapy may lie in identifying biological agents
for targeted chemotherapy. Tyrosine kinase inhibitors may
be a viable option as abl is expressed in up to 45% of uterine
carcinosarcomas, Her-2 in19%andPDGFRβ in100%.Addi-
tional potential targets expressed by these tumours include
receptors to estrogen, progesterone, vascular endothelial
growth factor, cyclooxygenase 2 and epidermal growth factor
[52]. It is likely that further understanding of this rare
tumour will facilitate the identiﬁcation of additional poten-
tial antineoplastic targets. Elevated CA125 postoperatively
confers a 5.7x risk of death [32] and perhaps could aid
in early identiﬁcation of candidates for adjuvant radiation
and/or chemotherapeutic treatments. Postoperative mul-
timodal adjuvant therapy with sequential chemotherapy
followed by radiotherapy has to date shown no evidence of
measurable survival beneﬁt [7].Obstetrics and Gynecology International 9
9.RecurrenceandMetastases
Recurrences in uterine carcinosarcomas occur in over half
of patients after primary surgical and adjuvant therapy
[7]. Even in early-stage disease, rates of recurrence are
reported between 47%–64% [36] and up to 80% of these will
be associated with distant metastases [52]. Speciﬁc factors
that increase the risk of recurrence include patient age,
adnexal spread, metastases to the lymph nodes, tumour size,
lymphatic-vascular space involvement, histologic grade, cell
type, peritoneal cytologic ﬁndings, and the depth of invasion
of the primary tumour. Interestingly, on multivariate anal-
ysis, only adnexal spread, lymph-node metastases, sarcoma
cell type, and sarcomatous grade were positive predictors
of recurrence [7]. Most recurrences occur within one year
[14].
Local recurrences to the pelvis and abdomen are more
often the cause of death in patients with uterine carci-
nosarcoma than metastatic disease. Additionally, the dissem-
ination pattern of uterine carcinosarcoma is unpredictable.
Metastatic disease is reported to be related to positivity of
the retroperitoneal lymph nodes, deep myometrial invasion,
cervical tumour extension, vascular invasion, and a low-
degree of diﬀerentiation [1]. In contrast to sarcomas that
spread haematogenously, uterine carcinosarcomas behave
like endometrial carcinoma and spread through the lym-
phatics. It is not surprising then that the tumor emboli
retrieved from both within these lymphovascular channels
and the metastatic lesions almost always contain elements of
carcinoma with or without a coexisting sarcoma, and soli-
tary sarcomatous metastasis is uncommon [25]. Metastatic
uterine carcinosarcoma is usually clinically asymptomatic.
The most common sites of metastatic deposit include
the lung (49%), peritoneum (44%), pelvic or para-aortic
lymph nodes (35%), adrenal gland or bone (19%), heart or
pericardium (9%), and/or brain (7%) [31]. Additional sites
of metastases include the pancreas, liver, thyroid gland, eye,
and skin [53]. Uterine carcinosarcoma has the highest rate
of pulmonary metastases among uterine malignancies [45].
Recurrent or metastatic uterine carcinosarcomas are often
treated with chemotherapy [51].
10.Prognosis
Although uterine carcinosarcomas account for less than 5%
of all uterine malignancies, they are responsible for over 15%
of uterine cancer-related deaths [7]. Over the past thirty
years despite evolving and advancing therapeutic regimes,
prognosis remains poor, with no signiﬁcant improvement
in survival or recurrence rates [36]. Stage is reported as an
independent prognostic factor for overall survival in patients
with uterine carcinosarcoma [30]; however, the comparison
of survival data outcome in the published literature is
diﬃcult due to (a) lack of stage stratiﬁcation in major large
published series and (b) lack of standardization compared
to survival outcome data in endometrial carcinomas or
uterine leiomyosarcomas. Nevertheless, higher stage disease
is correlated well with decreased overall survival. 5-year
survival rates in early uterine carcinosarcomas (FIGO Stages
I/II) are between 30%–46%, and 0%–10% in advanced
cancers (FIGO Stages III/IV) [19]. The median survival
in patients with uterine carcinosarcoma ranges between 16
and 40 months [11] with death usually occurring within
1-2 years of the initial diagnosis [71]. The prognosis of
uterine carcinosarcoma is worse than that of endometrial
carcinoma with adjustment for known adverse prognostic
factors [25, 72]. The behaviour of uterine carcinosarcoma
has been likened to that of dediﬀerentiated endometrial
carcinoma [72]. This poor prognosis compared to other
uterine malignancies is primarily attributed to the high rates
of distant metastases and early recurrences often attributed
to the advanced stage at initial clinical presentation [17].
Prognostic features though well-studied in the literature
are reported with conﬂicting results. The most important
prognostic factor is the extent of tumour at initial presen-
tation, as extrauterine spread is associated with very poor
survival outcomes [14]. Older patients (over 70 years of
age) have been reported to have a poorer outcome than the
young, which may be attributed to preexisting comorbid
factors such as a poorer performance status resulting in less
aggressive therapy [30]; however, other literature does not
support this ﬁnding [29]. Oral contraceptives are protective
against uterine carcinosarcomas [25] whereas tamoxifen
increases the relative risk fourfold [33]. Preoperative levels of
CA125 are correlated with extrauterine disease and increased
myometrial invasion. Postoperative increases of CA125 have
been reported as a signiﬁcant independent prognostic factor
for death [32].
T u m o u rc h a r a c t e r i s t i c ss u c ha sm y o m e t r i a li n v a s i o no f
less than one-third of the uterus with no detectable metas-
tasis, and a size less than 7cm are all associated with a favou-
rable outcome in some reports [73]. Most studies agree that
deeper myometrial invasion increases the risk of extrauterine
extension [30] and on multivariant analysis stage has been
reported as the most important prognostic factor [55]a n d
predictor of patient outcome [74]. Other studies have not
found the initial tumour size to signiﬁcantly alter survival
rates [30]. Speciﬁcally in early-stage uterine carcinosarco-
mas, additional prognostic factors associated with a worse
outcome include lymphovascular space involvement, the
histology of the carcinomatous component, the extent of the
sarcomatous component, and the presence of heterologous
elements [74]. Homologous-type uterine carcinosarcoma
confers a better prognosis than the heterologous-type in
some studies [30], but this relationship is not supported
by others [29]. Positive peritoneal cytology is associated
with poor prognosis in uterine carcinosarcoma [10]. In
some studies, serous or clear cell carcinoma as the epithelial
element is associated with poorer survival outcomes [32].
T u m o u rc h a r a c t e r i s t i c so fm o l e c u l a rm a r k e r ss u c ha se x p r e s -
sion of p53 in older women are associated with a shorter
mean survival, while p53 negative tumours occurring in
younger women have a longer survival [24, 38]. Immuno-
histochemical tumour expression of other cell cycle and
apoptotic regulatory proteins such as p16 and Mcl-1 are also
associatedwithlongersurvivals[24,38,71].Trendsobserved
in such individual series are diﬃcult to generalize due to
small sample sizes and need to be validated as predictive10 Obstetrics and Gynecology International
Current recommendations for the treatment of uterine MMMT
Mainstay of treatment: comprehensive surgical staging
Stage I/II
Limited to uterus and cervix
Stage III
Extrauterine, intrapelvic
Stage IV
Extrauterine, extrapelvic
Advanced recurrent
persistent metastatic
Resection of gross abdominal
disease(cytoreductive surgery) +
+
radiation
+
?Single cytotoxic agent
?Combination treatment
?Targeted antineoplastic pharmacological interventions
?Molecular targeted therapy
Vaginal brachytherapy
Localized pelvic radiation
External beam radiation
Whole abdominal radiation
Total abdominal hysterectomy (TAH) + bilateral salpingo-oophorectomy (BSO)
+ peritoneal/pelvic washings + pelvic lymphadenectomy + para-aortic lymph
Node dissection (visual intraoperative + removal of any/all suspicious nodes) + omental biopsy
?Role for multimodal therapy
Sequential chemotherapy and radiation therapy
Adjuvant chemotherapy Adjuvant chemotherapy Adjuvant chemotherapy
?Role of cytoreductive surgery
Figure 5: This ﬂow chart summarizes the current recommendations for the treatment of uterine carcinosarcomas. Due to the rapidly
progressive nature of this neoplasm, we recommend adjuvant chemotherapy even in Stage I/II lesions as we believe that the late clinical
presentation of these cases is usually associated with silent microscopic disseminated disease. Uncertainties regarding the value of aggressive
cytoreductive surgery in Stage IV disease are questionable and indicated with “?”. Similarly, the most eﬀective protocol for chemotherapy is
also unknown and indicated by “?”. Likewise, the role for multimodal therapy in this neoplasm is yet to be determined (?).
and/or prognostic markers with further research in larger
tumour populations.
11. Conclusions
Uterine carcinosarcoma is a rare, highly aggressive, rapidly
progressing neoplasm associated with a poor prognosis that
has not signiﬁcantly improved in the past thirty years despite
advances in imaging and adjuvant therapies. Controversies
continue to linger in many areas of uterine carcinosar-
coma, as summarized in Table 2. The optimal management
modalityremainscontroversial,withdiscrepanciesregarding
patientoutcometolymphadenectomyandradiationtherapy.
Additionally, various chemotherapeutic protocols have been
attempted with varying results. There are no current con-
sensus guidelines for the management of this rare disease.
The rarity of this neoplasm resulting in small sample size
has precluded large trials for evaluation of various treatment
protocols. Yet, uterine carcinosarcoma though rare needs
to be recognized as a distinct entity, as it is highly aggres-
sive. To maximize the probability of cure with improved
survival outcomes the future of uterine carcinosarcomaObstetrics and Gynecology International 11
Table 2: Controversies in uterine carcinosarcoma.
(i) Origins: sarcomatous versus carcinomatous monoclonal versus
biclonal versus polyclonal.
(ii) Demographics: more common in Afro-American versus Cau-
casian women.
(iii) Aetiology: radiation inducible tumour versus metaplastic
versus dediﬀerentiation versus common stem cell.
(iv) Pathogenesis: collision theory versus combination theory
versus conversion theory.
(v) Risk factors: beneﬁcial eﬀect of oral contraceptives versus
detrimental eﬀect of exogenous estrogens.
(vi) Presentation: symptomatic (pyometra/vaginal bleeding/abdo-
minal pain) versus asymptomatic.
(vii)Microscopic:biphasiccomponents—separatedversusmerged.
(viii) MRI description: endophytic with architectural obliteration
versus exophytic with no invasiveness.
(ix) Sonography: diagnostic use—yes versus no technique—tran-
sabdominal versus transvaginal.
(x) Surgery: lymphadenectomy versus nolymph-node dissection.
(xi) Adjuvant therapy: radiotherapy versus chemotherapy versus
molecular targeted versus multimodality therapy.
(xii) Radiotherapy: locoregional control versus improved over-
all survival limited pelvic radiation versus whole abdominal
radiation.
(xiii) Chemotherapy: single-agent versus combination versus tar-
geted antineoplastic therapy.
( x i v )P r o g n o s t i cf e a t u r e s :?signiﬁcance of tumour size, patient age,
and histology of sarcomatous element.
managementistodevelopconsensusguidelinesoftreatment.
This can be realized by prospective multicentric, multi-
institutional collaborative randomized trials of treatment
protocols with novel multimodality strategies that include
a multidisciplinary approach of surgery, radiotherapy, and
potentially evolving speciﬁc systemic therapy with targeted
antineoplastic pharmacological interventions. In summary,
the current proposed recommendation for the management
of uterine carcinosarcoma is outlined in Figure 5.
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